Eflora CREAM (VANIQA)13.9%w/v

$36.60

Each Eflora cream contains 13.9% Eflornithine 15 grams and is used in the treatment of hirsutism (unwanted facial hair growth), in women.

ATC Classification: D11AX16, P01CX03
Active Ingrediant: Eflornithine Hydrochloride
Generic Name: Eflora CREAM
Manufacturer: Ranbaxy Limited
Strength: 13.9%w/v
Dosage Type: Cream
Packaging Type: Box
Contains: 15 gm

Eflora CREAM 13.9
Eflora CREAM (VANIQA)13.9%w/v
$36.60

 

Pronunciation

(ee FLOR ni theen)

 

Medication Safety Issues

Sound-alike/look-alike issues:

Vaniqa may be confused with Viagra

 

Storage/Stability

Cream: Store at controlled room temperature 25°C (77°F); excursions permitted to 15°C to 30°C (59 °F to 86°F); do not freeze.

Injection: Use within 24 hours of preparation.

 

Adverse Reactions

Injection (Priotto 2009):

Cardiovascular: Cardiac arrhythmia, chest pain, edema, hypertension, hypotension, shock

Central nervous system: Amnesia, anxiety, ataxia, coma, confusion, depression, dizziness, hallucination, headache, insomnia, lethargy, peripheral neuropathy, seizure

Dermatologic: Pruritus, skin rash

Endocrine & metabolic: Dehydration

Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dysgeusia, dysphagia, hiccups, nausea, vomiting, xerostomia

Genitourinary: Change in creatinine, urinary frequency, urinary incontinence, urinary urgency

Hematologic & oncologic: Anemia, leukopenia, neutropenia, thrombocytopenia

Hepatic: Abnormal bilirubin levels, increased serum transaminases

Infection: Infection

Local: Extravasation, injection site reaction

Neuromuscular & skeletal: Arthralgia, myalgia, tremor, weakness

Otic: Inner ear disturbance

Respiratory: Cough, dyspnea, epistaxis, respiratory distress

Miscellaneous: Fever

Additional information

Active Ingrediant

Generic Name

Alternate Names

, , , , , ,

Strength

Dosage Type

Packaging Type

Shipping From

Brand

Ranbaxy

Reviews

There are no reviews yet.

Be the first to review “Eflora CREAM (VANIQA)13.9%w/v”

Your email address will not be published. Required fields are marked *